Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $387204.0.

  • Atara Biotherapeutics' Gains from Sales and Divestitures rose 7481.31% to $387204.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $387204.0, marking a year-over-year increase of 7481.31%. This contributed to the annual value of $315109.0 for FY2024, which is 9145.58% down from last year.
  • Per Atara Biotherapeutics' latest filing, its Gains from Sales and Divestitures stood at $387204.0 for Q3 2025, which was up 7481.31% from $282988.0 recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year Gains from Sales and Divestitures high stood at $3.7 million for Q4 2023, and its period low was $65580.0 during Q1 2025.
  • Over the past 4 years, Atara Biotherapeutics' median Gains from Sales and Divestitures value was $480264.0 (recorded in 2023), while the average stood at $1.1 million.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 22597.24% in 2024, then crashed by 9581.1% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Gains from Sales and Divestitures (Quarter) stood at $2.2 million in 2022, then soared by 64.11% to $3.7 million in 2023, then tumbled by 91.46% to $315109.0 in 2024, then increased by 22.88% to $387204.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $387204.0 for Q3 2025, versus $282988.0 for Q2 2025 and $65580.0 for Q1 2025.